Ⅲ期非小细胞肺癌术后新辅助化疗的应用效果观察

Application Effect Observation of Postoperative Neoadjuvant Chemotherapy for StageⅢNon-Small Cell Lung Cancer

目的:探讨Ⅲ期非小细胞肺癌(NSCLC)术后新辅助化疗的应用效果。方法:选取2019年10月—2020年12月山东费县人民医院收治的67例NSCLC术后患者作为研究对象,根据随机数字表法分为对照组(33例)与研究组(34例)。对照组术后给予常规对症治疗,研究组术后给予新辅助化疗方案治疗。比较两组病情控制率、生活质量评分、肿瘤复发率与生存率。结果:研究组病情控制率高于对照组,差异有统计学意义(P=0.036)。治疗前,两组健康调查简表(SF-36)评分比较,差异无统计学意义(P=0.930);治疗后,两组SF-36评分高于治疗前,且研究组高于对照组,差异有统计学意义(P=0.000)。研究组肿瘤复发率低于对照组,无病生存率及总生存率均高于对照组,差异有统计学意义(P<0.05)。结论:新辅助化疗可提高Ⅲ期NSCLC患者术后生活质量,降低肿瘤近期复发率,提高1年内无病生存率及总生存率,临床疗效显著。

Objective:To explore the application effect of postoperative neoadjuvant chemotherapy for stageⅢnon-small cell lung cancer(NSCLC).Methods:A total of 67 postoperative patients with NSCLC treated in Shandong Feixian People's Hospital from October 2019 to December 2020 were selected as the study subjects.The patients were divided into control group(33 cases)and study group(34 cases)according to random number table method.The control group was given conventional symptomatic treatment,and the study group was given neoadjuvant chemotherapy.The disease control rate,quality of life score,tumor recurrence rate and survival rate were compared between the two groups.Results:The disease control rate in the study group was higher than that in the control group,and the difference was statistically significant(P=0.036).Before treatment,there was no significant difference in the scores of the 36-Item Short Form Health Survey(SF-36)between the two groups(P=0.930).After treatment,the SF-36 score in the two groups was higher than that before treatment,and the study group was higher than the control group,and the difference was statistically significant(P=0.000).The tumor recurrence rate in the study group was lower than that in the control group,and the disease-free survival rate and overall survival rate in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion:Neoadjuvant chemotherapy can improve the postoperative quality of life of patients with stageⅢNSCLC,reduce the short-term recurrence rate of tumor,and increase the disease-free survival rate and overall survival rate within 1 year.The clinical efficacy is significant.